Literature DB >> 15800786

Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes.

A Candoni, A Raza, F Silvestri, L Lisak, N Galili, M Mumtaz, F Kikic, R Fanin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15800786     DOI： 10.1007/s00277-005-1031-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  Thalidomide is a highly effective treatment of MDS: a single-hospital experience in Japan.

Authors:  Kunio Hayashi; Keiko Hattori; Fumiharu Toi
Journal:  Int J Hematol       Date:  2010-05       Impact factor: 2.490

Review 2.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.